NICE TA860 - Maribavir for treating refractory cytomegalovirus infection after transplant. NHSE commissioned. (Decision date - February 2023)
Treatment of cytomegalovirus infection and/or disease that are refractory (with or without resistance) to ≥1 prior therapies, in adults who have undergone a haematopoietic stem cell transplant or solid organ transplant. NHSE commissioned. (Decision date - March 2023)
Red Drug Classifications
8. NHS England commissioned – to be used in line with NHSE commissioning intentions
